By jurisdiction
European Union (EMA)
Every compound we track that has a recorded status under European Union (EMA). Tap a name for the full picture, including the U.S. status and primary sources.
| Compound | Status here | Note |
|---|---|---|
| AOD-9604 | Restricted | No EU marketing authorisation or orphan designation (absent from the Union Register); sale as a medicine is unlawful EU-wide, with enforcement at member-state level. |
| BPC-157 | Restricted | No EU marketing authorisation; sale as a medicine is unlawful EU-wide, with enforcement handled at member-state level. |
| Cagrilintide | Restricted | No EU marketing authorisation; not on EMA’s August 2026 list of applications under CHMP evaluation; sale as a medicine unlawful EU-wide, with enforcement at member-state level. |
| CJC-1295 | Restricted | No EU marketing authorisation; absent from the Union Register, so sale as a medicine is unlawful EU-wide, with enforcement handled at member-state level. |
| Dihexa | Restricted | No EU marketing authorisation or orphan designation (absent from the Union Register); sale as a medicine is unlawful EU-wide, with enforcement at member-state level. |
| Emideltide (DSIP) | Restricted | No EU marketing authorisation for emideltide (DSIP); sale as a medicine is unlawful EU-wide, with enforcement handled at member-state level. |
| Epitalon | Restricted | No EU marketing authorisation; sale as a medicine is unlawful EU-wide, with enforcement handled at member-state level. |
| GHK-Cu | Restricted | No EU marketing authorisation; sale as a medicine is unlawful EU-wide, with enforcement handled at member-state level. |
| Ipamorelin | Restricted | No EU marketing authorisation; absent from the Union Register, so sale as a medicine is unlawful EU-wide, with enforcement at member-state level. |
| Kisspeptin-10 | Restricted | No EU marketing authorisation and no EU orphan designation; absent from the Union Register, so sale as a medicine is unlawful EU-wide, with enforcement at member-state level. |
| KPV | Restricted | No EU marketing authorisation; not found in EMA’s centralised medicines database, so sale as a medicine is unlawful EU-wide, with enforcement handled at member-state level. |
| LL-37 (cathelicidin) | Restricted | No EU marketing authorisation or orphan designation (absent from the Union Register); sale as a medicine is unlawful EU-wide, with enforcement at member-state level. |
| Melanotan II | Restricted | No EU marketing authorisation - no melanotan II entry in EMA’s centrally authorised medicines database; sale as a medicine is unlawful EU-wide, with enforcement handled at member-state level. |
| MOTS-c | Restricted | No EU marketing authorisation in the Union Register; sale as a medicine is unlawful EU-wide, with enforcement handled at member-state level. |
| NAD+ | Restricted | No EU marketing authorisation; injectable NAD+ cannot be marketed as a medicine EU-wide, with enforcement handled at member-state level; oral NAD+ circulates under food-supplement law. |
| PT-141 (bremelanotide) | Restricted | No EU marketing authorisation: absent from the Union Register, and EMA’s medicines data lists no application for it. Enforcement against unlicensed supply is handled at member-state level. |
| Retatrutide | Restricted | No EU marketing authorisation and no application under CHMP evaluation as of August 2026; sale as a medicine is unlawful EU-wide, with enforcement handled at member-state level. |
| Selank | Restricted | No EU marketing authorisation; Selank does not appear in the Union Register, so sale as a medicine is unlawful EU-wide, with enforcement handled at member-state level. |
| Semaglutide (compounded) | Restricted | Centrally authorised prescription-only medicine; compounded versions hold no EU marketing authorisation, with enforcement against unlicensed supply handled at member-state level. |
| Semax | Restricted | No EU marketing authorisation; sale as a medicine is unlawful EU-wide, with enforcement handled at member-state level. |
| Sermorelin | Restricted | No centralised EU marketing authorisation (absent from the Union Register); sale as a medicine is unlawful EU-wide, with enforcement handled at member-state level. |
| SS-31 (elamipretide) | Restricted | No EU marketing authorisation. Holds EU orphan designations for Barth syndrome (May 20, 2021) and myopathic mitochondrial DNA depletion syndrome (May 16, 2022), which EMA says do not mean the medicine is authorised. |
| TB-500 (Thymosin Beta-4) | Restricted | No EU marketing authorisation; sale as a medicine is unlawful EU-wide, with enforcement handled at member-state level. |
| Tesamorelin | Restricted | No EU marketing authorisation: Ferrer Internacional withdrew its application for Egrifta on June 21, 2012, when the CHMP’s provisional opinion was that it could not have been approved. |
| Thymosin Alpha-1 | Restricted | No EU-wide EMA marketing authorisation - thymalfasin holds only an orphan designation (EU/3/02/110) - and is reported as nationally authorised on prescription in Italy as Zadaxin. |
| Tirzepatide (compounded) | Restricted | Licensed prescription-only medicine EU-wide (Mounjaro, authorised 2022); unauthorised versions cannot be marketed, with pharmacy compounding exemptions and enforcement handled at member-state level. |